HK Stock Market Move | CARSGEN-B(02171) rose over 46% in the afternoon, with impressive clinical data for the universal CAR-T product CT0590.

date
07/11/2024
avatar
GMT Eight
CARSGEN-B (02171) rose over 46% in the afternoon, reaching a 33.19% increase by the time of writing, trading at 6.3 Hong Kong dollars with a turnover of 277 million Hong Kong dollars. On the news front, on November 6th, Ke Ji Pharmaceutical announced that data on Saikai Ze (Zevorcyllin sylate injection), CT071, and CT0590 will be presented in poster form at the 66th Annual American Society of Hematology (ASH) Conference, which will be held from December 7th to 10th. The summaries of the aforementioned products have already been published on the ASH official website. Among them, the first-in-man Phase I trial data for Ke Ji Pharmaceutical's BCMA-targeted universal CAR-T CT0590 showed that out of 5 enrolled subjects, with a median follow-up time of 16.6 months (range: 5.1 to 24.2 months), 3 patients achieved remission. This included 2 sCR and 1 PR cases. Among the 2 sCR patients, one RRMM patient had a duration of remission (DOR) of 23 months (sCR is still ongoing), and the other pPCL patient had a DOR of 20 months. In these 2 sCR patients, the peak CAR copy number exceeded 280,000 copies/g genomic DNA. Preliminary results of the study suggest that the safety of the universal CAR-T cell therapy CT0590 is manageable while achieving deep and long-lasting clinical remission.

Contact: contact@gmteight.com